Imugene Limited (ASX:IMU) may trade firmer after the Israeli Patent Office issued an Intention to Grant for its proprietary cancer vaccine, HER-Vaxx.
The patent will protect specific cancer vaccine formulations in Israel until 2027.
HER-Vaxx stimulates a polyclonal antibody response to the HER-2/neu receptor, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.
HER-2/neu is known to be over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers.
HERVaxx has completed a Phase 1 study in breast cancer; the next stage of development will be a Phase 2 study in gastric cancer, which is the second most common cause of cancer-related death in the world
Imugene secured full rights to manufacture the cancer immunotherapy as part of its acquisition of BioLife Science in December last year.
The first patent was assigned from Pevion Biotech of Switzerland, protecting Her-Vaxx in several major markets until 2030.
Imugene also holds an exclusive global license covering a patent for the virosome vaccine delivery platform, which is used in the vaccine's manufacture.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.